A phase I trial of ublituximab (TG-1101), a novel glycoengineered anti-CD20 monoclonal antibody (mAb) in B-cell non-Hodgkin lymphoma patients with prior exposure to rituximab.
Owen A. O'Connor
Research Funding - TG Therapeutics
Changchun Deng
Research Funding - TG Therapeutics
Jennifer Effie Amengual
Research Funding - TG Therapeutics
Mazen Y. Khalil
Research Funding - TG Therapeutics
Marshall T. Schreeder
Research Funding - TG Therapeutics
Daruka Mahadevan
Research Funding - TG Therapeutics
Petros Nikolinakos
Research Funding - TG Therapeutics
Ahmed Sawas
Research Funding - TG Therapeutics
Jasmine M. Zain
Research Funding - TG Therapeutics
Molly Patterson
Research Funding - TG Therapeutics
Amber Moon
Research Funding - TG Therapeutics
Emily K. Pauli
Research Funding - TG Therapeutics
Kathy Cutter
Research Funding - TG Therapeutics
Michelle Ann Mackenzie
Research Funding - TG Therapeutics
Marnie Brotherton
Research Funding - TG Therapeutics
Jamie Hodgson
Research Funding - TG Therapeutics
Christen N Cooper
Research Funding - TG Therapeutics
Peter Sportelli
Employment or Leadership Position - TG Therapeutics
Stock Ownership - TG Therapeutics
Hari P. Miskin
Employment or Leadership Position - TG Therapeutics
Stock Ownership - TG Therapeutics
Charles Michael Farber
Honoraria - TG Therapeutics
Research Funding - TG Therapeutics